LetterLetter
Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis–associated Uveitis
ESTEFANIA QUESADA-MASACHS and CONSUELO MODESTO CABALLERO
The Journal of Rheumatology February 2017, 44 (2) 260-261; DOI: https://doi.org/10.3899/jrheum.160908
ESTEFANIA QUESADA-MASACHS
Department of Rheumatology, Pediatric Rheumatology Unit, Hospital Universitario Vall d’Hebron;
MDCONSUELO MODESTO CABALLERO
Department of Rheumatology, Pediatric Rheumatology Unit, Hospital Universitario Vall d’Hebron, Barcelona,
Spain.
MD, PhDREFERENCES
- 1.↵
- Brunner HI,
- Ruperto N,
- Zuber Z,
- Keane C,
- Harari O,
- Kenwright A,
- et al.
- 2.↵
- 3.↵
- 4.↵
- Tappeiner C,
- Heinz C,
- Ganser G,
- Heiligenhaus A
- 5.↵
- 6.↵
- Nguyen QD,
- Sadiq MA,
- Chu DS,
- Dacey MS,
- Gallemore RP,
- Dayani PN,
- et al.
- 7.↵
- Burmester GR,
- Rubbert-Roth A,
- Cantagrel A,
- Hall S,
- Leszczynski P,
- Feldman D,
- et al.
- 8.↵
- 9.↵
- 10.↵
- 11.↵
- Brunner HI,
- Lovell DJ,
- Finck BK,
- Giannini EH
In this issue
The Journal of Rheumatology
Vol. 44, Issue 2
1 Feb 2017
Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis–associated Uveitis
ESTEFANIA QUESADA-MASACHS, CONSUELO MODESTO CABALLERO
The Journal of Rheumatology Feb 2017, 44 (2) 260-261; DOI: 10.3899/jrheum.160908